On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Objective To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.Materials and Methods This retrospective co...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Maryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven R. Feldman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2026-12-01
Serie:	Journal of Dermatological Treatment
Soggetti:	On-label persistence psoriasis guselkumab advanced therapies real-world evidence
Accesso online:	https://www.tandfonline.com/doi/10.1080/09546634.2026.2631903
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!